Overview

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
All
Summary
The main objective of the study will be to test the hypothesis that treatment with Liraglutide will decrease ER stress and adipose tissue in obese patients with type 2 diabetes. Experimental Approach: The investigators will use a prospective, single blind, placebo controlled study design to study 12 obese patients with type 2 diabetes mellitus (T2DM). 6 patients will first receive Liraglutide for 24 weeks followed by placebo for 12 weeks. The other 6 patients will first receive placebo for 12 weeks followed by Liraglutide for 24 weeks. Measurements: The investigators will determine glycemic control (with HbA1c), body composition (bioelectric impedance analysis), insulin sensitivity (with hyperinsulinemic-euglycemic clamps), insulin secretion (with oral glucose tolerance testing), energy balance (calories in vs. calories out), plasma lipid levels and obtain subcutaneous fat biopsies to determine ER stress response markers before and after placebo and before and after Liraglutide treatment.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Temple University
Treatments:
Liraglutide
Criteria
Inclusion Criteria:

- Patients with established type 2 diabetes, BMI 27-35, Age - 18-75 years, HbA1c 7-10%,
patients treated with exercise, diet, metformin and/or alpha glucosidase inhibitors
(all up to ½ of their maximal dose) or pioglitazone (up to 30 mg/d), ability to
provide informed consent before any trial-related activities.

Exclusion Criteria:

- Patients with pancreatitis or a history of pancreatitis, patients with HbA1c < 7% or >
10%, type 2 diabetic patients treated with insulin, sulfonylureas, meglitinides, DPP4
inhibitors, GLP1 agonists or corticosteroids, patients with hypoglycemia unawareness
and with impaired liver functions (≥ 2.5 times the upper normal limit), known or
suspected allergy against liraglutide or contraindications to liraglutide (as
specified in the product prescribing information), pregnancies, breastfeeding or
intention of becoming pregnant or not using adequate contraceptive measures, patients
with a personal or family history of medullary thyroid cancer and patients with
Multiple Endocrine Neoplasia type 2.